首页> 美国卫生研究院文献>Blood >Gene Therapy: Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection
【2h】

Gene Therapy: Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection

机译:基因治疗:通过串联阵列转染有效构建用于SCID-X1基因治疗的SIN慢病毒载体生产细胞系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Retroviral vectors containing internal promoters, chromatin insulators, and self-inactivating (SIN) long terminal repeats (LTRs) may have significantly reduced genotoxicity relative to the conventional retroviral vectors used in recent, otherwise successful clinical trials. Large-scale production of such vectors is problematic, however, as the introduction of SIN vectors into packaging cells cannot be accomplished with the traditional method of viral transduction. We have derived a set of packaging cell lines for HIV-based lentiviral vectors and developed a novel concatemeric array transfection technique for the introduction of SIN vector genomes devoid of enhancer and promoter sequences in the LTR. We used this method to derive a producer cell clone for a SIN lentiviral vector expressing green fluorescent protein, which when grown in a bioreactor generated more than 20 L of supernatant with titers above 107 transducing units (TU) per milliliter. Further refinement of our technique enabled the rapid generation of whole populations of stably transformed cells that produced similar titers. Finally, we describe the construction of an insulated, SIN lentiviral vector encoding the human interleukin 2 receptor common γ chain (IL2RG) gene and the efficient derivation of cloned producer cells that generate supernatants with titers greater than 5 × 107 TU/mL and that are suitable for use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).
机译:相对于最近在其他方面取得成功的临床试验中使用的常规逆转录病毒载体,包含内部启动子,染色质绝缘子和自灭活(SIN)长末端重复序列(LTR)的逆转录病毒载体可能具有显着降低的遗传毒性。但是,这种载体的大规模生产是有问题的,因为不能用传统的病毒转导方法将SIN载体引入包装细胞。我们已经为基于HIV的慢病毒载体衍生了一套包装细胞系,并开发了一种新型的串联体阵列转染技术,用于在LTR中引入缺乏增强子和启动子序列的SIN载体基因组。我们使用此方法衍生了表达绿色荧光蛋白的SIN慢病毒载体的生产者细胞克隆,该克隆在生物反应器中生长时,产生超过20 L的上清液,滴度高于10 7 转导单位(TU)每毫升。我们技术的进一步完善使得能够快速产生稳定滴度稳定的完整转化细胞群。最后,我们描述了编码人白介素2受体共同γ链(IL2RG)基因的绝缘SIN慢病毒载体的构建,以及克隆的生产细胞的高效衍生,这些细胞产生的滴度大于5×10 7 TU / mL,适用于X连锁严重联合免疫缺陷症(SCID-X1)的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号